Santé log

EssilorLuxottica va acquérir Signifeye, poursuivant l’extension de son réseau de cliniques ophtalmologiques

Paris, France (12 décembre 2025) – EssilorLuxottica a annoncé aujourd’hui l’acquisition de Signifeye, une plateforme d’ophtalmologie belge de premier plan qui propose aux patients des prestations ...
Santé log

EssilorLuxottica to acquire Signifeye, further growing its ophthalmology clinics footprint

Paris, France (12 December 2025) – EssilorLuxottica announced today the acquisition of Signifeye, a leading Belgian ophthalmology platform delivering top-tier patient care across 15 eye centers and ...
Santé log

Tenaya Therapeutics Announces Pricing of Public Offering

Tenaya intends to use the net proceeds from the offering to fund the ongoing and planned development of its clinical and early-stage product candidates, particularly TN-201 and TN-401, and for working ...
Santé log

Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

Mesoblast’s Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved ...
Santé log

Surgery Partners, Inc. Announces Pricing of Add-On Notes Offering

Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) today announced that its wholly-owned subsidiary, Surgery Center Holdings, Inc. (the “Issuer”), priced $425.0 million ...
Santé log

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Terns Pharmaceuticals is a clinical-stage oncology company reimagining known biology to deliver high impact medicines. Our lead program TERN-701 is a highly selective, allosteric BCR-ABL inhibitor ...
Santé log

FDA Approves the Zenflow Spring® Implant and Delivery System for First-Line Interventional Therapy of Patients with Benign Prostatic Hyperplasia (BPH)

U.S. Food and Drug Administration (FDA) approval of the Zenflow Spring ® Implant and Delivery System for the treatment of symptoms associated with benign prostatic hyperplasia (BPH), also known as ...
Santé log

Health Care Advocates Slam Ford Government for Privatizing Surgeries While Pushing Public Hospitals into Deficit

The Coalition notes that the Ford government has been paying 20% more for each surgery in private cataract clinics and more than 200% more per surgery to the private hospital for which their former ...
Santé log

Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock

WARREN, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 230,000 of his ...
Santé log

Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...
Santé log

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

Prior to joining Serina, Dr. Thomas served in progressive scientific leadership roles at Mersana Therapeutics, where during his 13 years he played a pivotal part in building out their discovery ...